# US 11,993,589 B2 · Prodigiosin analogs and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,993,589 B2
- Document ID: US11993589B2
- Status: Granted
- Kind: B2
- Application number: 18/076,778
- Filed: 2022-12-07
- Published: 2023-10-05
- Granted: 2024-05-28
- Earliest claimed: 2016-04-08
- Assignees: Institute For Cancer Research
- Applicants: Institute For Cancer Research
- Inventors: Wafik S. El-Deiry; Xiaobing Tian
- Web page: https://patentgrep.com/patent/US11993589B2

## CPC

- C07D 403/14: containing three or more hetero rings
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.

## Claims

### Claim 1

A method of treating colorectal cancer in a subject, the method comprising administering to the subject a compound of formula:
or tautomer or solvate thereof, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is in a composition including a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound is in a composition including a pharmaceutically acceptable excipient.

### Claim 4 (depends on 2)

The method of claim 2, wherein the composition is a liquid dosage form.

### Claim 5 (depends on 2)

The method of claim 2, wherein the composition is a solid dosage form.

### Claim 6 (depends on 1)

The method of claim 1, further comprising administering to the subject another anti-cancer therapy.

### Claim 7 (depends on 6)

The method of claim 6, wherein the another anti-cancer therapy is radiation therapy, chemotherapy, or immunotherapy, or any combination thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the colorectal cancer is associated with a p53 gain of function (GOF) mutation.